The latest price target for Cara Therapeutics (NASDAQ:CARA) was reported by Canaccord Genuity on June 13, 2024. The analyst firm set a price target for $1.00 expecting CARA to rise to within 12 months (a possible 207.60% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for Cara Therapeutics (NASDAQ:CARA) was provided by Canaccord Genuity, and Cara Therapeutics downgraded their hold rating.

The last upgrade for Cara Therapeutics Inc happened on March 8, 2022 when JP Morgan raised their price target to $20. JP Morgan previously had a neutral for Cara Therapeutics Inc.

The last downgrade for Cara Therapeutics Inc happened on June 13, 2024 when Canaccord Genuity changed their price target from $10 to $1 for Cara Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cara Therapeutics was filed on June 13, 2024 so you should expect the next rating to be made available sometime around June 13, 2025.

While ratings are subjective and will change, the latest Cara Therapeutics (CARA) rating was a downgraded with a price target of $10.00 to $1.00. The current price Cara Therapeutics (CARA) is trading at is $0.33, which is out of the analyst’s predicted range.